TY - JOUR

T1 - Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models

AU - Volgin, Andrey D.

AU - Yakovlev, Oleg A.

AU - Demin, Konstantin A.

AU - Alekseeva, Polina A.

AU - Kyzar, Evan J.

AU - Collins, Christopher

AU - Nichols, David E.

AU - Kalueff, Allan V.

PY - 2019/1/16

Y1 - 2019/1/16

N2 - Hallucinogenic drugs potently alter human behavior and have a millennia-long history of use for medicinal and religious purposes. Interest is rapidly growing in their potential as CNS modulators and therapeutic agents for brain conditions. Antimuscarinic cholinergic drugs, such as atropine and scopolamine, induce characteristic hyperactivity and dream-like hallucinations and form a separate group of hallucinogens known as "deliriants". Although atropine and scopolamine are relatively well-studied drugs in cholinergic physiology, deliriants represent the least-studied class of hallucinogens in terms of their behavioral and neurological phenotypes. As such, novel approaches and new model organisms are needed to investigate the CNS effects of these compounds. Here, we comprehensively evaluate the preclinical effects of deliriant hallucinogens in various animal models, their mechanisms of action, and potential interplay with other signaling pathways. We also parallel experimental and clinical findings on deliriant agents and outline future directions of translational research in this field.

AB - Hallucinogenic drugs potently alter human behavior and have a millennia-long history of use for medicinal and religious purposes. Interest is rapidly growing in their potential as CNS modulators and therapeutic agents for brain conditions. Antimuscarinic cholinergic drugs, such as atropine and scopolamine, induce characteristic hyperactivity and dream-like hallucinations and form a separate group of hallucinogens known as "deliriants". Although atropine and scopolamine are relatively well-studied drugs in cholinergic physiology, deliriants represent the least-studied class of hallucinogens in terms of their behavioral and neurological phenotypes. As such, novel approaches and new model organisms are needed to investigate the CNS effects of these compounds. Here, we comprehensively evaluate the preclinical effects of deliriant hallucinogens in various animal models, their mechanisms of action, and potential interplay with other signaling pathways. We also parallel experimental and clinical findings on deliriant agents and outline future directions of translational research in this field.

KW - antimuscarinic agents

KW - deliriants

KW - Hallucinogens

KW - rodents

KW - zebrafish

KW - ZEBRAFISH DANIO-RERIO

KW - PREPULSE INHIBITION

KW - LOCOMOTOR-ACTIVITY

KW - PREFRONTAL CORTEX

KW - LYSERGIC-ACID DIETHYLAMIDE

KW - INDUCED MEMORY IMPAIRMENT

KW - MUSCARINIC RECEPTOR ANTAGONISTS

KW - SCOPOLAMINE-INDUCED DISRUPTION

KW - WORKING-MEMORY

KW - COGNITIVE DEFICITS

UR - http://www.scopus.com/inward/record.url?scp=85055153870&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/understanding-central-nervous-system-effects-deliriant-hallucinogenic-drugs-through-experimental-ani

U2 - 10.1021/acschemneuro.8b00433

DO - 10.1021/acschemneuro.8b00433

M3 - Review article

AN - SCOPUS:85055153870

VL - 10

SP - 143

EP - 154

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 1

ER -